Evidence map›Paper›PMID 39170628›Full record

ArticleFrontiers in veterinary science2024

Assessment of the potential risks in SD rats gavaged with genetically modified yeast containing the

Bo Bi, Xuewei Fu, Xuewen Jian, Yu Zhang, Yizhi Jiang, Wuyi Zhou, Hui Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in veterinary science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bo Bi *Key Laboratory for Biobased Materials and Energy of Ministry of Education, Research Center of Biomass 3D Printing Materials, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
Xuewei Fu *Key Laboratory for Biobased Materials and Energy of Ministry of Education, Research Center of Biomass 3D Printing Materials, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
Xuewen JianKey Laboratory for Biobased Materials and Energy of Ministry of Education, Research Center of Biomass 3D Printing Materials, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
Yu ZhangKey Laboratory for Biobased Materials and Energy of Ministry of Education, Research Center of Biomass 3D Printing Materials, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
Yizhi JiangGuangzhou Zhixin High School, Guangzhou, China.
Wuyi ZhouKey Laboratory for Biobased Materials and Energy of Ministry of Education, Research Center of Biomass 3D Printing Materials, College of Materials and Energy, South China Agricultural University, Guangzhou, China.
Hui ZhaoKey Laboratory for Biobased Materials and Energy of Ministry of Education, Research Center of Biomass 3D Printing Materials, College of Materials and Energy, South China Agricultural University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Despite the absence of definitive evidence indicating that the cp4-epsps gene and its resultant recombinant proteins have significant harmful effects on either human or animal health, the safety assessment of genetically modified (GM) crops expressing the CP4-EPSPS proteins has been controversial. This study endeavor was aimed at evaluating the potential risks posed by the CP4-EPSPS protein in transgenic crops, thereby contributing to the advancement of risk assessment methodologies in the context of genetically engineered crops. Methods: To ascertain the appropriate daily dosages for oral gavage administration, the expression levels of the CP4-EPSPS protein in a recombinant yeast were quantified. Subsequently, physiological and biochemical analysis, metabolomics, and metagenomic analysis were conducted based on a 90-day Sprague-Dawley (SD) rats feeding experiment, respectively, thereby enhancing the depth and precision of our risk assessment framework. Results: The results from the physiological and biochemical analysis, organ pathological, blood metabolism, gut microbiota, and correlation analysis of metabolites and gut microbiota revealed several biomarkers for further risk assessment. These biomarkers include clinical biochemical indexes such as total bilirubin (TBIL), direct bilirubin (DBIL), creatine kinase (CK), and lactate dehydrogenase (LDH); metabolites like Methionine, 2-Oxovaleric acid, and LysoPC (16:0); and gut microbiota including Conclusion: In conclusion, the risk can be significantly reduced by directly consuming inactivated recombinant CP4-EPSPS. Therefore, in everyday life, the risk associated with consuming GM foods containing recombinant CP4-EPSPS is substantially reduced after heat treatment.

Indexed as

biomarkersCP4-EPSPS proteinfood safetygut microbiomemetabolomics

Identifiers

PMID39170628
PMCPMC11335726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.